BeiGene (BSP:B1ME34) Total Tax Payable : R$662 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is BeiGene Total Tax Payable?

BeiGene's Total Tax Payable for the quarter that ended in Mar. 2025 was R$662 Mil.

BeiGene's quarterly Total Tax Payable increased from Sep. 2024 (R$274 Mil) to Dec. 2024 (R$371 Mil) and increased from Dec. 2024 (R$371 Mil) to Mar. 2025 (R$662 Mil).

BeiGene's annual Total Tax Payable increased from Dec. 2022 (R$231 Mil) to Dec. 2023 (R$260 Mil) and increased from Dec. 2023 (R$260 Mil) to Dec. 2024 (R$371 Mil).

BeiGene Total Tax Payable Historical Data

The historical data trend for BeiGene's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Total Tax Payable Chart

BeiGene Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Tax Payable

Get a 7-Day Free Trial

178.79

379.20

230.82

259.86

371.15

BeiGene Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Tax Payable	Get a 7-Day Free Trial															371.26	289.47	273.73	371.15	662.44

BeiGene Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

BeiGene Total Tax Payable Related Terms

Thank you for viewing the detailed overview of BeiGene's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (BSP:B1ME34) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

BEIGF:USA ONC:USA 06160:Hong Kong 49B:Germany 49B:Germany 49BA:Germany 49BA:Germany 688235:China

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeiGene Headlines

No Headlines